Morbilliform drug reaction with histologic features of pustular dermatosis associated with bryostatin-1.
Bryostatin-1 is a new chemotherapeutic agent that inhibits protein kinase C. The most common side effect and the dose limiting toxicity is myalgia. The cutaneous side effects reported during the phase I and II trials were alopecia, mucositis, nonspecific "rash," "bronzing," and hyperpigmentation in sun exposed areas. No specific acute drug eruptions have been reported. We present the first reported case of a morbilliform drug eruption with histologic features of intraepidermal and subcorneal spongiotic pustules containing eosinophils secondary to bryostatin-1.
Krejci-Manwaring
Jennifer M
JM
Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Bogle
Melissa A
MA
Diwan
Hafeez A
HA
Duvic
Madeleine A
MA
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects*; D054713:Bryostatins; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D018942:Macrolides; D008297:Male; D008875:Middle Aged; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D013274:Stomach Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D054713:Bryostatins; D007783:Lactones; D018942:Macrolides; C046785:bryostatin 1; D011493:Protein Kinase C